Cellebrite grants director 15,190 RSUs
Director Troy Richardson received a compensation-related RSU grant that will vest into additional Cellebrite DI Ltd. (CLBT) Ordinary Shares in 2027.
Rhea-AI Filing Summary
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Richardson Troy reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Troy Richardson received a grant of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU settling into one Ordinary Share. Following this award, Richardson directly holds 36,164 Ordinary Shares. The grant carries a stated price of $0.00 per share, indicating a compensation-related equity award rather than a market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary shares, par value NIS 0.00001 F1 | 15,190 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents an award of restricted share units ("RSUs") that will vest on September 17, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.
Key Figures
Key Terms
contingent right financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did director Troy Richardson report in this Form 4 for CLBT?
When do Troy Richardson’s new RSUs in CLBT vest?
Was Troy Richardson’s CLBT RSU grant a market purchase or a compensation award?
Is Troy Richardson’s CLBT Form 4 transaction under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.